icon-folder.gif   Conference Reports for NATAP  
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
Efficacy of sofosbuvir and simeprevir-based regimens for HCV treatment-experienced GT1 patients in a real-life setting; data from the TRIO network
  Reported by Jules Levin AASLD 2014 Nov 7-11 Boston
Bruce Bacon1, Douglas Dieterich2, Steven Flamm3, Kris Kowdley4, Eric Lawitz5, Scott Milligan6, Zobair Younossi7and Naoky Tsai8 1Saint Louis University School of Medicine, 2Mount Sinai School of Medicine, 3Northwestern University Feinberg School of Medicine, 4Swedish Liver Center and Transplant Program, Swedish Medical Center, 5The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, 6Trio Health Analytics,7Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, 8Queens Medical Center, University of Hawaii
AASLD: Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network - Academic and community treatment of a real-world, heterogeneous population - (11/10/14)
AASLD: Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort HCV-TARGET - (11/10/14)